Search results
Added:
2 months ago
Added:
10 months ago
THT Conference 2025 - Outcomes after heart failure patients were treated with an interatrial shunt show heart failure with reduced ejection fraction (HFrEF) patients had further benefit compared to heart failure with preserved ejection fraction (HFpEF) patients. The study's prediction model revealed four independent predictors of two-year adverse outcomes in HFrEF patients treated with medical…
View more
Added:
1 month ago
TCT 25 - Dr Raj Makkar (Cedars-Sinai Medical Center, US) joins us to discuss the findings on the EVOQUE Valve (Edwards Lifesciences) drawing from data in the STS/ACC Transcatheter Valve Therapy Registry.The study evaluated procedural success rates, in-hospital complications, and 30-day clinical outcomes in patients undergoing transcatheter tricuspid valve replacement for severe tricuspid…
View more
Added:
6 months ago
EuroPCR25 - Findings from TRINITY trial show favourable outcomes with the LuX-Valve Plus TTVR system in high-risk patients with severe tricuspid regurgitation.We are joined by Prof Thomas Modine (CHU de Bordeaux, Bordeaux, FR) to discuss key findings from the TRINITY trial. This prospective, single-arm, multi-center study evaluated the LuX-Valve Plus transjugular tricuspid valve replacement…
View more
Added:
1 year ago
AHA Conference 2024 - New insights from the CLEAR OUTCOMES trial investigating bempedoic acid (Esperion Therapeutics Inc.) in statin-intolerant patients with peripheral arterial disease (PAD).Dr Marc Bonaca (University of Colorado School of Medicine, Colorado, US) joins us onsite at AHA Conference to discuss new insights from CLEAR OUTCOMES (NCT02993406).CLEAR OUTCOMES is a double-blind,…
View more
Added:
2 months ago
HFSA 25 - Sex-specific outcomes of tirzepatide in obesity-related HFpEF showed that at baseline, women with HFpEF had more severe heart failure symptoms.Dr Barry Borlaug (Mayo Clinic, US) joins us to discuss a prespecified secondary analysis from the SUMMIT trial, examining sex-specific effects of tirzepatide in patients with heart failure with preserved ejection fraction and obesity.The SUMMIT…
View more
Added:
3 months ago
ESC Congress 2025 - New findings from STRIDE further demonstrate effectiveness of semaglutide in improving functional outcomes in PAD.Dr Subodh Verma joins us to discuss new findings from the STRIDE study, which investigated semaglutide 1.0mg in individuals with peripheral artery disease (PAD). 792 participants were enrolled in the trial, 24.6% of which were female, and 75.4% male.Findings showed…
View more
Added:
9 months ago
Added:
4 months ago
Explore the challenges and outcomes of TAVI in bicuspid aortic stenosis with Prof Ole De Backer (Rigshospitalet, Copenhagen, Denmark).This presentation, part of a comprehensive two-part series on complex cases in interventional cardiology, examines the unique anatomical considerations and clinical evidence when treating bicuspid valve disease with transcatheter techniques.Prof De Backer addresses…
View more
Added:
3 months ago
ESC Congress 2025 - New findings from a post-hoc analysis of TRISCEND II show that TTVR can reduce the rate of heart failure hospitalisations, particularly in the case of patients who present with massive or torrential TR - irrespective of baseline TR severity.Prof Philipp Lurz (University Mainz, DE) discusses new findings from the TRISCEND II trial, examining how baseline tricuspid regurgitation…
View more